Genelabs GL701 Lupus NDA Will Be Complete In Second Half Of 2000
Executive Summary
Genelabs' NDA filing plans for the potential lupus treatment GL701 (prasterone) will put the product on track for FDA action in early 2001.
You may also be interested in...
Genelabs/Watson Aslera Lupus Deal Includes $30.5 Mil. In Up-Front Payments
Watson Pharmaceuticals is investing $30.5 mil. up front to help Genelabs Technologies bring its systemic lupus erythematosus treatment Aslera (prasterone) to market, the companies jointly announced Nov. 13.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011